INDBInternet News Database 2.5 Updated 1 min ago · 293 sources Show or hide images Light or dark

Darolutamide Improves Metastasis-Free Survival in Very High-Risk Prostate Cancer

1 source1 article First seen Updated United States Truth score 38

Save Like Comments Compare coverage
Image from Medpagetoday

Summary

(MedPage Today) -- Adding darolutamide (Nubeqa) to androgen deprivation therapy (ADT) and radiation therapy significantly improved metastasis-free survival in patients with very high-risk prostate cancer, according to findings from the phase III...

Description from Medpagetoday.

Who is covering this

  1. Medpagetoday Center Factuality: Mostly factual US
    Darolutamide Improves Metastasis-Free Survival in Very High-Risk Prostate Cancer

    (MedPage Today) -- Adding darolutamide (Nubeqa) to androgen deprivation therapy (ADT) and radiation therapy significantly improved metastasis-free survival in patients with very high-risk prostate cancer, according to findings from the phase III...

Comments

Comments need JavaScript.